Section
This article highlights the discovery that TYK2 kinase is a selective therapeutic target in CALR-mutant myeloproliferative neoplasms, with combined TYK2 and JAK2 inhibition offering enhanced efficacy over JAK2 inhibition alone.
This review elucidates fibrocytes’ critical role in JAK2V617F-mutated myelofibrosis pathogenesis and evaluates pitavastatin’s promising therapeutic effects in reversing marrow fibrosis and anemia, integrating mechanistic insights and
Recent advances in identifying leukemia-restricted antigens enable subtype-specific immunotherapies in AML that selectively target malignant cells while sparing normal hematopoiesis, offering a promising new paradigm for precision treatment
Aberrant MERTK expression activates BCR signaling via CD79a in CLL, offering a novel therapeutic target. Inhibiting MERTK with UNC-2025 shows potential against ibrutinib-resistant relapse, especially combined with venetoclax.
Final phase 3 trial analysis confirms recombinant ADAMTS13 (rADAMTS13) provides effective prophylaxis with fewer acute and subacute TTP events and better safety than plasma-based therapy in congenital TTP patients.
This article elucidates how the TCA cycle enzyme IDH3 critically regulates metabolic fitness in AML stem cells, influencing venetoclax resistance and offering a novel target to improve therapeutic outcomes.
A comprehensive single-cell RNA sequencing study of large B cell lymphomas reveals five malignant B cell archetypes, with one subtype predictive of poor treatment response and survival, paving the way for precision therapy in LBCL.
Measurable residual disease (MRD) testing offers critical insights to tailor allogeneic hematopoietic cell transplantation in adults with acute myeloid leukemia, optimizing patient selection, conditioning intensity, and relapse surveillance
Soluble BCMA levels in newly diagnosed multiple myeloma patients reveal distinct tumor phenotypes and predict prognosis more strongly than tumor volume, enabling improved risk stratification and clinical decision-making.
This study reveals that lifelong genetic differences in LDL cholesterol levels do not significantly affect the risk of venous thromboembolism (VTE), suggesting LDL-C may not be a major causal factor in VTE development.
This study elucidates the incidence and characteristics of respiratory viral infections (RVIs) within 100 days following hematopoietic cell transplant and CAR T-cell therapy, highlighting SARS-CoV-2 as the predominant pathogen and identifyi
The addition of tyrosine kinase inhibitors to intensive chemotherapy markedly improves remission rates and overall survival in patients with de novo BCR::ABL1+ acute myeloid leukemia, suggesting a new standard of care approach.
This article explores the pivotal role of IGF2BP2, an N6-methyladenosine reader, in driving tumor growth and immune evasion in peripheral T-cell lymphoma, highlighting its potential as a dual-action therapeutic target.
This review synthesizes cutting-edge findings on how genetic and nongenetic RAS-pathway activation mediates resistance to combined FLT3 and BCL2 inhibition in acute myeloid leukemia, highlighting implications for treatment strategies and bi
This study identifies plasma proteomic signatures linked to clonal hematopoiesis driver mutations and develops a proteomic risk score that independently predicts adverse clinical outcomes in heart failure with preserved ejection fraction (H
A large Spanish study reveals the shifting landscape of GVHD prophylaxis in alloHSCT, highlighting widespread post-transplant cyclophosphamide use and its impact on acute and chronic GVHD incidence and survival outcomes.
T-cell lymphomas after CAR T-cell therapy are exceedingly rare but significant. This article reviews incidence, mechanisms, diagnostic challenges, and clinical implications to guide vigilance without overshadowing CAR T-cell therapy’s
Maintenance therapies—lenalidomide, thalidomide, and bortezomib—significantly improve survival after autologous stem cell transplant for multiple myeloma, regardless of initial response status, based on a large global registry analysis.
This study clinically validates an AI-based quantitative tool, CIF, for bone marrow fibrosis assessment, demonstrating improved reproducibility and accuracy over manual grading without increasing assessment time.
This study identifies an IL-17A/PTGS2/NLRP3 signaling axis as a key driver of immune suppression and myeloproliferation in PTPN11-mutant JMML, demonstrating that combined inflammasome and PTGS2 inhibition with MEK blockade improves survival
